Evaluation of survivin immunoexpression in the differentiation of high- and low-grade breast ductal carcinoma in situ

Autor: Enio Martins Medeiros, Maria Antonieta Longo Galvão, Milca Cézar Chade, Sebastião Piato, Romulo Negrini, José Mendes Aldrighi, Evandro Falaci Mateus
Rok vydání: 2018
Předmět:
0301 basic medicine
In situ
Pathology
medicine.medical_specialty
medicine.drug_class
Survivin
Biomarcadores tumorais
Clone (cell biology)
lcsh:Medicine
Breast Neoplasms
Monoclonal antibody
03 medical and health sciences
0302 clinical medicine
Biomarkers
Tumor
Proteínas de neoplasias
Humans
Medicine
skin and connective tissue diseases
Carcinoma
intraductal
noninfiltrating
Inhibitor of apoptosis proteins
Carcinoma intraductal não infiltrante
business.industry
Carcinoma in situ
Carcinoma
Ductal
Breast
Proteínas inibidoras de apoptose
lcsh:R
Neoplasias da mama
General Medicine
Ductal carcinoma
medicine.disease
Immunohistochemistry
Staining
030104 developmental biology
Neoplasm proteins
030220 oncology & carcinogenesis
Biomarkers
tumor
Original Article
Female
Breast neoplasms
business
Carcinoma in Situ
Zdroj: Einstein (São Paulo), Vol 16, Iss 1
einstein (São Paulo) v.16 n.1 2018
Einstein (São Paulo)
Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE)
instacron:IIEPAE
Einstein
ISSN: 2317-6385
1679-4508
DOI: 10.1590/s1679-45082018ao4065
Popis: Objective To evaluate the expression of survivin protein in low- and high-grade ductal carcinoma in situ. Methods Breast tissue fragments obtained by incisional biopsy and surgical procedures of 37 women with ductal carcinoma in situ of the breast were subdivided into two groups: Group A, composed of women with low-grade ductal carcinoma in situ, and Group B, women with high-grade ductal carcinoma in situ. Survivin protein expression test was performed by immunohistochemistry, using a monoclonal antibody clone I2C4. The criterion to evaluate survivin immunoexpression was based on the percentage of neoplastic cells that presented brown-gold staining. This criterion was positive when the percentage of stained cells was ≥10%. Results The survivin protein was expressed in 22 out of 24 cases of high-grade ductal carcinoma in situ (78%), whereas, in Group A, of low-grade ductal carcinoma in situ (n=13), it was positive in only 6 cases (21.40%; p=0.004). Conclusion The frequency of expression of survivin was significantly higher in the group of patients with high-grade ductal carcinoma in situ compared to those in the low-grade ductal carcinoma in situ group.
Databáze: OpenAIRE
Externí odkaz: